General
Preferred name
LEVETIRACETAM
Synonyms
ETIRACETAM ()
UCB L059 ()
SIB-S1 ()
LEVETIRACETAM102767-28-2 ()
Levetiracetam (UCB-L059) ()
UCB-L059, SIB-S1 ()
Spritam ()
Keppra Xr ()
Levetiracetam sun ()
Elepsia ()
UCB 22059 ()
Levetiracetam hospira ()
NSC-760119 ()
UCB-L059 ()
AGB-101 ()
Levetiracetam In Sodium Chloride ()
UCB-22059 ()
Levetiracetam actavis ()
N03AX14 ()
Levetiracetam accord ()
Levetiracetam teva ()
Desitrend ()
Elepsia XR ()
Keppra ()
Levetiracetame ()
Matever ()
Levetiracetam-d6 ()
P&D ID
PD001324
CAS
102767-28-2
1133229-30-7
Tags
available
drug
Approved by
FDA
PMDA
EMA
First approval
1999
Drug indication
Fibromyalgia
Epilepsy
Drug Status
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION In addition to being assigned an INN in its own right, levetiracetam is the biologically active enantiomer of racemic formulation etiracetam, also assigned an INN.
Levetiracetam is the active compound in Spritam®, the first 3D printed pill to be approved by the US FDA (in August 2015). (GtoPdb)
DESCRIPTION p53-stabilizing agent (Tocris Bioactive Compound Library)
DESCRIPTION Antiepileptic; binds SV2A (Tocriscreen Plus)
DESCRIPTION Anticonvulsant; antiepileptic; exact mechanism of action is unclear but may be related to a synaptic vesicle protein. (LOPAC library)
Compound Sets
32
Axon Medchem Screening Library
1110
Cayman Chemical Bioactives
9001820
26457
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL1286
ChEMBL Drugs
CHEMBL1286
Concise Guide to Pharmacology 2017/18
6826
Concise Guide to Pharmacology 2019/20
6826
Concise Guide to Pharmacology 2021/22
6826
Concise Guide to Pharmacology 2023/24
6826
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB01202
DrugBank Approved Drugs
DB01202
DrugCentral
1563
DrugCentral Approved Drugs
1563
DrugMAP
DMTGDN8
DrugMAP Approved Drugs
DMTGDN8
Enamine BioReference Compounds
Guide to Pharmacology
6826
LOPAC library
Mcule NIBR MoA Box Subset
MCULE-8756188475
NCATS Inxight Approved Drugs
44YRR34555
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Levetiracetam
TargetMol Bioactive Compound Library
T0192
The Spectrum Collection
Tocris Bioactive Compound Library
2839
Tocriscreen Plus
2839
External IDs
48
Properties
(calculated by RDKit )
Molecular Weight
170.11
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
1
Rotatable Bonds
3
Ring Count
1
Aromatic Ring Count
0
cLogP
-0.13
TPSA
63.4
Fraction CSP3
0.75
Chiral centers
1.0
Largest ring
5.0
QED
0.64
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Voltage-gated N-type calcium channel alpha-1B subunit
mAChR
Synaptic vesicle glycoprotein 2A
Calcium Channel
CACNA1B, SCN1A, SV2A
Anticonvulsant
AChR,Calcium Channel
Target Type
Cell Biology
Pathway
Neuronal Signaling
GPCR/G protein
Membrane Transporter/Ion Channel
MOA
synaptic vesicle glycoprotein 2A modulator
calcium channel blocker
Primary Target
Translocation, Exocytosis & Endocytosis
Member status
member
Indication
seizures
Therapeutic Class
Anticonvulsants
Source data